2 completed, 1 terminated. 2 Phase 4, 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 2 | Completed 1, Terminated 1 |
| Phase 2 | 1 | Completed 1 |
| Phase 3 | 1 | Completed 1 |
Follow Frederick Health: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Nebulized Heparin for the Treatment of COVID-19 Heparin, 0.9%sodium chloride - Covid19, Pneumonia, Viral | Phase 4 | Completed | Frederick Health | 50 | 2021-02-22 | 2021-09-05 |
| Nebulized Heparin for the Treatment of COVID-19 Induced Lung Injury Heparin, 0.9% Sodium-chloride - Covid-19, ARDS, Human | Phase 4 | Terminated | Frederick Health | 13 | 2020-06-01 | 2024-04-03 |
| Inhaled Heparin for Hospitalised COVID-19 Patients Unfractionated heparin - Covid19 | Phase 2 / Phase 3 | Completed | Australian National University | 485 | 2020-06-01 | 2025-06-17 |
COVID-19 (3) · Acute Lung Injury (1) · Pneumonia, Viral (1) · Respiratory Distress Syndrome (1)
Heparin (3) · Sodium Chloride (2)
United States (2) · Argentina (1) · Egypt (1) · Indonesia (1)
Frank MP van Haren, MD, PhD (1)